Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

GSK Sees Blockbuster Chronic Cough Opportunity With $2bn Bellus Buyout

Potential Best-In-Class Drug

Apr 18 2023

• By Andrew McConaghie

• Source: GSK

Related Content

Hiccup For Evotec As Bayer Pulls Plug On Chronic Cough Drug

Feb 07 2022

GSK To Take ‘Smart Risks’ Across Portfolio – But Will Be ‘Pragmatic’ About Oncology Expansion

Nov 02 2022

Merck's Gefapixant CRL Dashes Hopes For Another Near-Term Growth Driver

Jan 24 2022

Related Companies

GSK plc

BELLUS Health Inc.

Bayer AG

Merck & Co., Inc.

Sierra Oncology, Inc.

Affinivax, Inc.

Scynexis, Inc.

Spero Therapeutics, Inc.

Pfizer Inc.

Seagen Inc.

Additional Topics

M & A Companies Commercial Deals Respiratory BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.